Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Trial details
- Registry ID
- NCT04016805
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Calquence
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxNCT04016805 | TGTX | Phase 2 | Terminated | 2022-05-22Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |